Table 2 Sensitivity of TIS LoVo colon carcinoma cells to BH3 mimetics.
From: Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
IC50 (μmol/L) ± SD | ||||
|---|---|---|---|---|
ABT-263/navitoclax | A1331852 | ABT-199/venetoclax | S63845 | |
Proliferative (untreated) | 7.56 ± 1.19 (1) | 8.98 ± 1.61 (1) | 19.37 (1) | >20 (1) |
Palbociclib TIS | 7.35 ± 1.45 (1) | 2.82 ± 0.28 (3.2) | >20 (<1) | >20 (1) |
Alisertib TIS | 4.63 ± 1.61 (1.6) | 0.01 ± 0.01 (898) | 13.89 (1.4) | >20 (1) |